See more : LiveXLive Media, Inc. (LIVX) Income Statement Analysis – Financial Results
Complete financial analysis of Sharps Technology, Inc. (STSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sharps Technology, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Pearl Holdings Acquisition Corp (PRLHW) Income Statement Analysis – Financial Results
- Empresa Metropolitana de Águas e Energia S.A. (EMAE3.SA) Income Statement Analysis – Financial Results
- Askari Metals Limited (AS2.AX) Income Statement Analysis – Financial Results
- NGEx Minerals Ltd. (NGXXF) Income Statement Analysis – Financial Results
- Semper Paratus Acquisition Corporation (LGST) Income Statement Analysis – Financial Results
Sharps Technology, Inc. (STSS)
About Sharps Technology, Inc.
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 891.25K | 654.57K | 28.70K | 11.04K | 10.59K |
| Gross Profit | -891.25K | -654.57K | -28.70K | -11.04K | -10.59K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.61M | 2.28M | 1.69M | 827.01K | 388.02K |
| General & Administrative | 8.52M | 6.46M | 2.81M | 1.51M | 1.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.66M |
| SG&A | 8.52M | 6.46M | 2.81M | 1.51M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.13M | 8.74M | 4.50M | 2.33M | 2.05M |
| Cost & Expenses | 10.13M | 8.74M | 4.50M | 2.33M | 2.06M |
| Interest Income | 0.00 | 1.32K | 769.00 | 3.33K | 3.60K |
| Interest Expense | 138.12K | 1.32M | 167.52K | 0.00 | 0.00 |
| Depreciation & Amortization | 891.25K | 654.57K | 28.70K | 11.04K | 10.59K |
| EBITDA | -8.98M | -2.66M | -4.47M | -2.33M | -2.04M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.13M | -8.74M | -4.50M | -2.33M | -2.06M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 255.01K | 4.10M | -166.75K | -6.87K | 3.59K |
| Income Before Tax | -9.87M | -4.64M | -4.66M | -2.34M | -2.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -30.00K | -5.42M | 166.75K | 6.87K | 3.00 |
| Net Income | -9.84M | 779.89K | -4.83M | -2.35M | -2.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.76 | 0.10 | -0.53 | -0.26 | -0.22 |
| EPS Diluted | -0.76 | 0.10 | -0.53 | -0.26 | -0.22 |
| Weighted Avg Shares Out | 13.03M | 8.10M | 9.17M | 9.17M | 9.17M |
| Weighted Avg Shares Out (Dil) | 13.03M | 8.10M | 9.17M | 9.17M | 9.17M |
What's Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?
Shares of Sharps Technology Inc STSS are trading higher on Friday, with a heavy session volume of 15.17 million.
Sharps Technology Receives Purchase Orders for 1 Million SecureGard Syringes for 2024 Delivery
Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies issues purchase orders for 1mL SecureGard ultra-low waste, smart safety syringes
Sharps Technology Ships First Orders for Securegard Disposable Smart Safety Syringes to Strategic Distribution Partner in Colombia
Orders for Sharps Securegard 1mL and 3mL syringes are on the water, introducing a line of competitively priced, low waste, smart safety syringes to the Colombian Healthcare System and the Latin American Market Orders for Sharps Securegard 1mL and 3mL...
Join Sharps Technology's Exclusive Live Investor Webinar and Q&A Session on June 18
NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at...
Why Is Sharps Technology (STSS) Stock Up 21% Today?
Sharps Technology (NASDAQ: STSS ) stock is up on Thursday after the medical device company announced a $30 million purchase order for its specialty copolymer prefillable syringes. Sharps Technology says this purchase order comes from Nephron Pharmaceuticals.
Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility
Signed PO secures first 12 months of syringe product orders against Sharps and Nephron's five-year, $200 million Syringe Sales Agreement.
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June...
Sharps Technology's SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.
Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S.
3 Penny Stocks Trading Abnormal Volume Today
As the overall market trades just 1.5% away from its all-time high and up over 4% on the month, there has been a noticeable increase in risk appetite and speculation in small-cap penny stocks by retail investors. This surge in...
Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.
Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S.
Source: https://incomestatements.info
Category: Stock Reports